全文获取类型
收费全文 | 15875篇 |
免费 | 799篇 |
国内免费 | 297篇 |
专业分类
耳鼻咽喉 | 148篇 |
儿科学 | 551篇 |
妇产科学 | 135篇 |
基础医学 | 1954篇 |
口腔科学 | 147篇 |
临床医学 | 1911篇 |
内科学 | 1883篇 |
皮肤病学 | 71篇 |
神经病学 | 2656篇 |
特种医学 | 558篇 |
外科学 | 1685篇 |
综合类 | 1464篇 |
一般理论 | 1篇 |
预防医学 | 997篇 |
眼科学 | 563篇 |
药学 | 1298篇 |
1篇 | |
中国医学 | 503篇 |
肿瘤学 | 445篇 |
出版年
2023年 | 262篇 |
2022年 | 426篇 |
2021年 | 663篇 |
2020年 | 517篇 |
2019年 | 553篇 |
2018年 | 547篇 |
2017年 | 491篇 |
2016年 | 405篇 |
2015年 | 505篇 |
2014年 | 988篇 |
2013年 | 1053篇 |
2012年 | 840篇 |
2011年 | 977篇 |
2010年 | 780篇 |
2009年 | 728篇 |
2008年 | 757篇 |
2007年 | 651篇 |
2006年 | 593篇 |
2005年 | 456篇 |
2004年 | 415篇 |
2003年 | 353篇 |
2002年 | 267篇 |
2001年 | 292篇 |
2000年 | 240篇 |
1999年 | 233篇 |
1998年 | 207篇 |
1997年 | 216篇 |
1996年 | 197篇 |
1995年 | 171篇 |
1994年 | 165篇 |
1993年 | 140篇 |
1992年 | 150篇 |
1991年 | 131篇 |
1990年 | 120篇 |
1989年 | 113篇 |
1988年 | 119篇 |
1987年 | 99篇 |
1986年 | 94篇 |
1985年 | 137篇 |
1984年 | 108篇 |
1983年 | 87篇 |
1982年 | 83篇 |
1981年 | 100篇 |
1980年 | 93篇 |
1979年 | 80篇 |
1978年 | 70篇 |
1977年 | 61篇 |
1976年 | 67篇 |
1975年 | 37篇 |
1973年 | 38篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
目的 观察结肠癌HCT116细胞健脾消癌方的条件培养液对HUVEC细胞管腔形成的影响,从PI3K/Akt生物轴调控角度探讨其作用机制。方法 培养HCT116细胞,细胞设3组:对照组,健脾消癌方组(加入15%健脾消癌方含药血清)及人参皂苷Rg3组;制备HCT116细胞健脾消癌方条件培养液(分组及制备方法见实验方法),用条件培养液干预HUVEC(脐静脉内皮细胞,Human Umbilical Vein Endothelial Cells),Matrigel基质胶法检测HCT116细胞健脾消癌方条件培养液对HUVEC小管形成的影响。随后采用蛋白免疫印迹法(Western blot)检测各组HCT116细胞磷脂酰肌醇3-激酶(PI3K)、蛋白激酶B(Akt)、p-Akt、VEGF(血管内皮生长因子,Vascular endothelial growth factor)蛋白表达。最后在结肠癌HCT116荷瘤小鼠中验证健脾消癌方对肿瘤生长速度的影响,并经瘤组织VEGF蛋白表达、CD31免疫组化染色检测肿瘤内血管生成情况。结果 模型组HUVEC细胞管腔形成较空白血清组显著增加(P<0.05);健脾消癌方组及人参皂苷Rg3组较模型组HUVEC细胞管腔形成显著减少(P<0.01)。p-Akt和VEGF蛋白表达水平模型组高于空白血清组(P<0.05),健脾消癌方组及人参皂苷Rg3组显著低于模型组(P<0.01);PI3K、Akt蛋白表达量组间差异无统计学意义。与对照组比较,模型组荷瘤小鼠肿瘤体积显著性增大,瘤组织内VEGF表达、CD31阳性面积显著性增加,差异有统计学意义(P<0.05);与模型组比较,健脾消癌方组及人参皂苷Rg3组荷瘤小鼠肿瘤体积显著减小,瘤组织内VEGF表达、CD31阳性面积降低,差异有统计学意义(P<0.05)。结论 健脾消癌方可抑制肿瘤的血管生成和生长,其作用机制可能与PI3K/Akt生物轴调控VEGF表达有关。 相似文献
2.
3.
4.
《Journal of Radiology Nursing》2022,41(3):166-169
PurposeIn 2018, The Journal of Vascular and Interventional Radiology (JVIR) updated its guidelines regarding periprocedural antibiotics. However, some institutions are slower to adopt these new guidelines. Additionally, antibiotic-resistant bacteria and sepsis are serious concerns due in part to incorrect usage of antibiotics. The purpose of this study is to assess institutional adherence to 2018 JVIR guidelines for the purpose of improving antibiotic stewardship.Materials and methodsA total of 800 cases over a 10-month time period were retrospectively identified and charted following the release of guidelines. Inclusion criteria for the study were adults aged 21 years or older undergoing mediport placement, tunneled central line (TCL) placement, nephrostomy tube exchange, percutaneous biliary drain, or cholecystostomy tube exchange. Exclusion criteria included immunocompromised and pregnant individuals as 2018 guidelines may not fit these patient populations. Guideline adherence for each procedure was recorded as a percentage; the timing of the antibiotic usage was also recorded and compared to the guidelines (within 60 minutes before incision).ResultsIn total, 49 mediport placements, 118 tunneled central line placements – 44 hemodialysis (HD) catheters and 74 nonhemodialysis (non-HD) catheters, 100 nephrostomy exchanges, and 82 biliary tube exchanges were included. Antibiotics were used in 83.6% (41/49) of mediport patients, 11.3% (5/44) of non-HD TCL patients, 20.5% (15/74) of HD TCL patients, 55% (55/100) nephrostomy tube changes, and 65.4% (55/84) of biliary or cholecystostomy tube exchanges. Out of those given prophylaxis, guideline-recommended antibiotics were used in 100% (41/41) of mediport, 100% (20/20) of TCL (both HD and non-HD catheters), 9% (5/55) of nephrostomy tube exchanges, and 1.8% (1/55) of biliary tube exchanges. Guideline-recommended timing was followed in 75.3% across all cases (ranging from 72.2% in mediports to 79.3% in biliary exchanges).ConclusionThis study of antibiotic practices at a single university-based academic institution revealed that antibiotic usage is not fully up to date with 2018 guidelines. For mediports, non-HD TCL placements, and nephrostomy tube exchanges, institutional changes should be made to reduce periprocedural antibiotic use, as antibiotics are no longer recommended for these procedures. For HD TCL and biliary exchanges, proper adherence to recommended prophylactic antibiotics should be followed. In addition, education about the correct antibiotic timing should be emphasized to increase compliance with guidelines. 相似文献
5.
Alexander E. J. Trevatt David R. Thomson Robert Miller Matthew Colquhoun Akinyemi I. Idowu Shakeel Rahman 《Journal of plastic surgery and hand surgery》2019,53(2):97-104
Academic output is just one aspect of a successful career as a plastic surgeon. However, for those with a strong interest in academia, the academic output of a department will likely be a key factor when deciding how to rank jobs. The aim of this study was to quantify and rank the academic output of plastic surgery units across the UK and Ireland. The Institute for Scientific Information (ISI) Web of Science Bibliometric analysis tool was used to collate cumulative (1950–2016), 10 year (2006–2016) and 3 years (2013–2015) research output data for plastic surgery units in the UK and Ireland. Sixty-six plastic surgery units were identified. Departments were ranked for each time period according to the number of papers produced, number of citations (Nc) and h-index (a measure of the impact of scientific output). The top 3 departments for number of papers in the last 10 years were The Royal Free Hospital, London (226) Broomfield Hospital, Chelmsford (218), and Morriston Hospital and Swansea (188). The top 3 for h-number were The Royal Free Hospital (21) Wythenshawe Hospital, Manchester (18) and Morriston Hospital (17). Academic output varies across plastic surgery units in the UK and Ireland. A number of departments have consistently maintained high academic outputs across the years and will be of interest to surgeons hoping to pursue a career in academia. 相似文献
6.
7.
《Neurologic Clinics》2019,37(2):425-440
8.
目的:探讨TomoTherapy QualityAssurance(TQA)数据趋势与螺旋断层放疗(Helical Tomotherapy,HT)系统输出的
联系。方法:回顾性分析了本院HT系统近3年内TQA各个模块的参数和数据趋势,探讨其与HT系统的静态输出剂量和
输出能量(D20/D10)变化的相关性。结果:楔形阶梯静态模块的z轴偏移参数与HT的静态输出剂量的相关性最强(r=0.883,
P<0.01)。基本剂量测定模块的出口检测器平整度值对能量变化最敏感(r=0.902),其次是楔形阶梯静态模块的能量差异
(r=0.897)和楔形阶梯螺旋模块的能量差异(r=0.852),灵敏度分别为2.3×10-4、3.1×10-4和5.7×10-4。结论:TQA有助于用户
追踪HT输出剂量和能量变化,及早进行必要的机器维护或剂量校准。 相似文献
9.
10.